BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Rebuffs Novartis Pharma AG (NVS) Over Delay To Biogeneric Drug


11/15/2005 11:16:25 AM

The U.S. Food and Drug Administration has asked a U.S. court to dismiss a lawsuit from a unit of Novartis AG alleging undue regulatory delays in deciding on its copycat human growth hormone drug, Omnitrope. Sandoz, the generics arm of the Swiss drug maker, sued the agency in September for leaving the product in limbo -- in a move designed to break a logjam over so-called biogenerics. The FDA argued in its defence that the charges were unfounded, since its experts had not finished their review. In its response filed in the U.S. District Court in Washington this week, the FDA admitted that it did not request additional information for Omnitrope's new drug application but denied that its professional scientific and review staff had completed their review of the application. The FDA did not disclose any reason why the application should be either approved or rejected. Sandoz said in a statement it remained confident of an eventual positive decision.

Read at Reuters


Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->